Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
about
A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy.Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcomeThe Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?Ranibizumab for the treatment of wet AMD: a summary of real-world studies.Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration.Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.
P2860
Q33825750-F304920F-CF09-4266-8938-1847741746DFQ35503206-B968E28E-EB41-498B-91CC-F269F792BAA8Q35716443-CA6950A1-9F36-4EE4-BA79-79C1F65D345EQ37407241-85D096FE-30A1-44D4-BB04-CD23878FE6A1Q37578627-90B72FEC-BD45-4F81-A80D-9DEDB18C621DQ37702363-8F566A85-83EB-4CDB-942F-D9F2E062DDB5Q38094076-627710ED-6578-4461-A1D3-9DE676D75245Q38103913-4810D391-285B-4D0E-8066-8AE709239897Q38592591-24C229CA-2931-46FA-A004-AD11116DCDA5Q38712425-BB199C8C-FF93-408F-8A53-D0750C9E7BAAQ44558337-709DB205-8174-47DA-82AC-733357D86E84
P2860
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Measuring the benefit of 4 yea ...... -related macular degeneration.
@en
type
label
Measuring the benefit of 4 yea ...... -related macular degeneration.
@en
prefLabel
Measuring the benefit of 4 yea ...... -related macular degeneration.
@en
P2093
P1476
Measuring the benefit of 4 yea ...... -related macular degeneration.
@en
P2093
Andrew C Browning
Evripidis Sykakis
Kinnar Merchant
Rajen Gupta
S James Talks
Sreekumari Pushpoth
P304
P356
10.1136/BJOPHTHALMOL-2012-302167
P407
P577
2012-09-21T00:00:00Z